Swk Hldgs Corp (SWKH) 1.4600 $SWKH
SWK Holdings Corporation Announces Up to Approximately $115 Million Equity Financing
GlobeNewswire - Mon Aug 18, 4:55PM CDT
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"
, a life science focused specialty finance company, announced that on August 18, 2014 that it has entered into a Securities Purchase Agreement (the "Purchase Agreement" and related documents with Carlson Capital, L.P. and affiliates ("Carlson" whereby in a series of transactions funds affiliated with Carlson (the "Stockholder" will purchase new shares in the Company such that its ownership increases to 69.0%.
Response Genetics reports launch of USD12.0m credit facility
M2 - Wed Aug 06, 6:29AM CDT
Molecular diagnostic company Response Genetics (NasdaqCM:RGDX) reported on Tuesday the execution of up to USD12.0m credit agreement with SWK Funding (SWK), a wholly-owned subsidiary of SWK Holdings ( agent).
Response Genetics Secures $12.0 Million Credit Facility
GlobeNewswire - Tue Aug 05, 6:08AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, and SWK Funding LLC ("SWK" , a wholly-owned subsidiary of SWK Holdings Corporation, as the agent, entered into a credit agreement (the "Credit Agreement" pursuant to which the lenders party thereto provide Response Genetics (the "Company" a term loan in the principal amount up to $12.0 million (the "Loan" .
SWK Holdings Corporation Special Committee Responds to Carlson Capital Letter
GlobeNewswire - Mon Jun 23, 10:02AM CDT
The Special Committee of SWK Holdings Corporation (OTCBB:SWKH) ("SWK" or the "Company" , a life science focused specialty finance company, today issued the following statement regarding Carlson Capital's letter to the Special Committee dated June 20, 2014:
SWK Holdings Corporation Announces 2013 Fourth Quarter and Full-Year Financial Results
GlobeNewswire - Mon Mar 31, 9:27AM CDT
-- Net income and adjusted net income to SWK stockholders of $12.9 million, or $0.31 per share, and $3.0 million, or $0.07 per share, respectively, for fiscal year 2013 vs. a loss of $1.4 million, or $(0.03) per share, for 2012
InSite Vision receives USD1m in royalties from the sale of Besivance
M2 - Wed Feb 05, 4:47AM CST
US-based ophthalmologic company InSite Vision Incorporated (Other OTC:INSV) stated on Tuesday that Besivance 2013 net sales has generated an additional USD1m milestone payment.
InSite Vision Announces Achievement of the $1 Million Milestone From the Sale of Besivance(R) Royalty
Business Wire - Tue Feb 04, 7:30AM CST
InSite Vision Incorporated (OTCBB: INSV) today announced that Besivance 2013 net sales achieved the levels necessary to earn InSite Vision an additional $1 million milestone payment from the Besivance royalty purchasers, SWK Funding LLC, a wholly-owned subsidiary of SWK Holdings Corporation (OTCBB: SWKH), and Bess Royalty, L.P. The $16 million total cash consideration to InSite Vision included a $15 million upfront payment in April, 2013, and a $1 million milestone payment which will be paid this month. Besivance (besifloxacin ophthalmic suspension) 0.6% is marketed globally by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, for the treatment of bacterial conjunctivitis.
Parnell Accelerates Expansion Plans
PR Newswire - Mon Feb 03, 3:22PM CST
Parnell, Inc. has announced further expansion plans of its North American operations based in Overland Park, Kansas. Robert Joseph President & CEO said; "This week we completed a $25m debt refinancing with SWK Holdings, Corporation based in Dallas, Texas. This capital transaction will ensure the continued expansion of our dairy franchise and fund our varied pipeline across companion animal and production animal products". "SWK is very pleased to partner with Parnell to support the build out of the company's animal health franchise with non-dilutive capital," said Brett Pope, CEO of SWK Holdings Corporation. "The combination of the company's innovative dairy hormone business, excellent management team and global distribution provide a compelling platform for future value creation."
SWK Holdings Corporation Announces Closing of an Up to $30 Million Debt Financing
GlobeNewswire - Mon Sep 09, 7:00AM CDT
SWK Holdings Corporation (OTCQB:SWKH) ("SWK" or the "Company" , a life science focused specialty finance company, announced today that it has closed a credit facility of up to $30 million from a fund affiliated with Carlson Capital, L.P. ("Carlson" . The credit facility has a four-year term and provides financing against all of SWK's assets. In conjunction with the credit facility, SWK's Board of Directors has agreed to waive certain "NOL pill" provisions to allow Carlson to increase its ownership of the Company. Carlson has been SWK's largest shareholder since the fourth quarter of 2009 and currently owns approximately 28% of the Company's outstanding stock.
CRWESELECT Daily Stock Watch MVC Capital, Inc. (NYSE:MVC), Crown Equity Holdings Inc. (OTCQB:CRWE), and SWK Holdings Corporation (OTCQB:SWKH)
WorldStockWire - Fri Aug 09, 11:45AM CDT
CRWEselect.com, a division of Crown Equity Holdings Inc. (OTCQB:CRWE) tracks stocks daily and is pleased to offer its hot stock to watch . Our stock focus today is on:
SWK Holdings Corporation Announces the 2013 Annual Shareholders Meeting Will Be Held on September 18, 2013
GlobeNewswire - Thu Aug 01, 11:29AM CDT
SWK Holdings Corporation ("SWK" or the "Company" (SWKH:OB) today announced that it has set Wednesday, September 18, 2013, as the date of its 2013 Annual Meeting of Stockholders (the "Annual Meeting" , and that the record date for determining stockholders entitled to vote at the Annual Meeting is Friday, August 16, 2013. The meeting will be held in Dallas, Texas. The deadline for stockholders to timely submit to the Company proposals to be brought before the Annual Meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended, is Monday, August 12, 2013. Pursuant to the Company's Bylaws, the deadline for stockholders to timely submit proposals to be brought before the Annual Meeting (except for proposals pursuant to Rule 14a-
and to nominate candidates for the Board of Directors is Monday, August 12, 2013.
InSite Vision Incorporated reports sale of Besivance royalty for up to USD16m
M2 - Wed Apr 03, 6:32AM CDT
Ophthalmologic company InSite Vision Incorporated (OTC Markets:INSV) said on Tuesday that it has agreed to sell its royalty on future sales of Besivance for up to USD16m.
InSite Vision Announces Sale of Besivance(R) Royalty for $15 Million Plus a $1 Million Potential Milestone in Early 2014
Business Wire - Tue Apr 02, 7:30AM CDT
InSite Vision Incorporated (OTCBB: INSV) today announced that it agreed to sell its royalty on future sales of Besivance(R), to SWK Funding LLC, a wholly-owned subsidiary of SWK Holdings Corporation (OTCBB: SWKH) and Bess Royalty, L.P. for up to $16 million. Besivance (besifloxacin ophthalmic suspension) 0.6% is marketed globally by Bausch + Lomb for the treatment of bacterial conjunctivitis.
SWK Holdings Corporation Announces Up to Approximately $115 Million Equity Financing
GlobeNewswire - Mon Aug 18, 4:55PM CDT
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"
, a life science focused specialty finance company, announced that on August 18, 2014 that it has entered into a Securities Purchase Agreement (the "Purchase Agreement" and related documents with Carlson Capital, L.P. and affiliates ("Carlson" whereby in a series of transactions funds affiliated with Carlson (the "Stockholder" will purchase new shares in the Company such that its ownership increases to 69.0%. Response Genetics reports launch of USD12.0m credit facility
M2 - Wed Aug 06, 6:29AM CDT
Molecular diagnostic company Response Genetics (NasdaqCM:RGDX) reported on Tuesday the execution of up to USD12.0m credit agreement with SWK Funding (SWK), a wholly-owned subsidiary of SWK Holdings ( agent).
Response Genetics Secures $12.0 Million Credit Facility
GlobeNewswire - Tue Aug 05, 6:08AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, and SWK Funding LLC ("SWK"
, a wholly-owned subsidiary of SWK Holdings Corporation, as the agent, entered into a credit agreement (the "Credit Agreement" pursuant to which the lenders party thereto provide Response Genetics (the "Company" a term loan in the principal amount up to $12.0 million (the "Loan" . SWK Holdings Corporation Special Committee Responds to Carlson Capital Letter
GlobeNewswire - Mon Jun 23, 10:02AM CDT
The Special Committee of SWK Holdings Corporation (OTCBB:SWKH) ("SWK" or the "Company"
, a life science focused specialty finance company, today issued the following statement regarding Carlson Capital's letter to the Special Committee dated June 20, 2014: SWK Holdings Corporation Announces 2013 Fourth Quarter and Full-Year Financial Results
GlobeNewswire - Mon Mar 31, 9:27AM CDT
-- Net income and adjusted net income to SWK stockholders of $12.9 million, or $0.31 per share, and $3.0 million, or $0.07 per share, respectively, for fiscal year 2013 vs. a loss of $1.4 million, or $(0.03) per share, for 2012
InSite Vision receives USD1m in royalties from the sale of Besivance
M2 - Wed Feb 05, 4:47AM CST
US-based ophthalmologic company InSite Vision Incorporated (Other OTC:INSV) stated on Tuesday that Besivance 2013 net sales has generated an additional USD1m milestone payment.
InSite Vision Announces Achievement of the $1 Million Milestone From the Sale of Besivance(R) Royalty
Business Wire - Tue Feb 04, 7:30AM CST
InSite Vision Incorporated (OTCBB: INSV) today announced that Besivance 2013 net sales achieved the levels necessary to earn InSite Vision an additional $1 million milestone payment from the Besivance royalty purchasers, SWK Funding LLC, a wholly-owned subsidiary of SWK Holdings Corporation (OTCBB: SWKH), and Bess Royalty, L.P. The $16 million total cash consideration to InSite Vision included a $15 million upfront payment in April, 2013, and a $1 million milestone payment which will be paid this month. Besivance (besifloxacin ophthalmic suspension) 0.6% is marketed globally by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, for the treatment of bacterial conjunctivitis.
Parnell Accelerates Expansion Plans
PR Newswire - Mon Feb 03, 3:22PM CST
Parnell, Inc. has announced further expansion plans of its North American operations based in Overland Park, Kansas. Robert Joseph President & CEO said; "This week we completed a $25m debt refinancing with SWK Holdings, Corporation based in Dallas, Texas. This capital transaction will ensure the continued expansion of our dairy franchise and fund our varied pipeline across companion animal and production animal products". "SWK is very pleased to partner with Parnell to support the build out of the company's animal health franchise with non-dilutive capital," said Brett Pope, CEO of SWK Holdings Corporation. "The combination of the company's innovative dairy hormone business, excellent management team and global distribution provide a compelling platform for future value creation."
SWK Holdings Corporation Announces Closing of an Up to $30 Million Debt Financing
GlobeNewswire - Mon Sep 09, 7:00AM CDT
SWK Holdings Corporation (OTCQB:SWKH) ("SWK" or the "Company"
, a life science focused specialty finance company, announced today that it has closed a credit facility of up to $30 million from a fund affiliated with Carlson Capital, L.P. ("Carlson" . The credit facility has a four-year term and provides financing against all of SWK's assets. In conjunction with the credit facility, SWK's Board of Directors has agreed to waive certain "NOL pill" provisions to allow Carlson to increase its ownership of the Company. Carlson has been SWK's largest shareholder since the fourth quarter of 2009 and currently owns approximately 28% of the Company's outstanding stock. CRWESELECT Daily Stock Watch MVC Capital, Inc. (NYSE:MVC), Crown Equity Holdings Inc. (OTCQB:CRWE), and SWK Holdings Corporation (OTCQB:SWKH)
WorldStockWire - Fri Aug 09, 11:45AM CDT
CRWEselect.com, a division of Crown Equity Holdings Inc. (OTCQB:CRWE) tracks stocks daily and is pleased to offer its hot stock to watch . Our stock focus today is on:
SWK Holdings Corporation Announces the 2013 Annual Shareholders Meeting Will Be Held on September 18, 2013
GlobeNewswire - Thu Aug 01, 11:29AM CDT
SWK Holdings Corporation ("SWK" or the "Company"
(SWKH:OB) today announced that it has set Wednesday, September 18, 2013, as the date of its 2013 Annual Meeting of Stockholders (the "Annual Meeting" , and that the record date for determining stockholders entitled to vote at the Annual Meeting is Friday, August 16, 2013. The meeting will be held in Dallas, Texas. The deadline for stockholders to timely submit to the Company proposals to be brought before the Annual Meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended, is Monday, August 12, 2013. Pursuant to the Company's Bylaws, the deadline for stockholders to timely submit proposals to be brought before the Annual Meeting (except for proposals pursuant to Rule 14a- and to nominate candidates for the Board of Directors is Monday, August 12, 2013. InSite Vision Incorporated reports sale of Besivance royalty for up to USD16m
M2 - Wed Apr 03, 6:32AM CDT
Ophthalmologic company InSite Vision Incorporated (OTC Markets:INSV) said on Tuesday that it has agreed to sell its royalty on future sales of Besivance for up to USD16m.
InSite Vision Announces Sale of Besivance(R) Royalty for $15 Million Plus a $1 Million Potential Milestone in Early 2014
Business Wire - Tue Apr 02, 7:30AM CDT
InSite Vision Incorporated (OTCBB: INSV) today announced that it agreed to sell its royalty on future sales of Besivance(R), to SWK Funding LLC, a wholly-owned subsidiary of SWK Holdings Corporation (OTCBB: SWKH) and Bess Royalty, L.P. for up to $16 million. Besivance (besifloxacin ophthalmic suspension) 0.6% is marketed globally by Bausch + Lomb for the treatment of bacterial conjunctivitis.
